Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05711732 · ClinicalTrials.gov registry record

Busulfan Sample Collection Study

A clinical trial of Subjects Treated With Busulfan, sponsored by Saladax Biomedical.

Recruiting
Registry status
150
Enrollment target
2
Study locations

NCT05711732 is a study of Subjects Treated With Busulfan that is actively recruiting participants, run by Saladax Biomedical. The registered enrollment target is 150 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05711732, a study of Subjects Treated With Busulfan, is actively recruiting participants, sponsored by Saladax Biomedical.

RECRUITING
Registry status
150 participants
Enrollment target
2
Study locations

Study Summary

Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.

Interventions

  • DIAGNOSTIC_TEST MyCare Oncology Busulfan Assay Kit

Study Locations (2)

Illinois

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-02-08
Est. Completion 2026-01-31

Sponsor

Saladax Biomedical

4 total trials

What the Registry Record Tells You About NCT05711732

The ClinicalTrials.gov registry entry for NCT05711732 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saladax Biomedical, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Subjects Treated With Busulfan appearing as the primary indexed condition, and to 1 intervention - of which MyCare Oncology Busulfan Assay Kit is the first listed.

NCT05711732 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Texas.

Frequently Asked Questions

What is clinical trial NCT05711732 about?

NCT05711732 is a clinical study titled "Busulfan Sample Collection Study". Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatmen...

What is the current status of trial NCT05711732?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-02-08. Estimated completion is 2026-01-31.

What conditions does trial NCT05711732 study?

This clinical trial studies the following conditions: Subjects Treated With Busulfan.

What interventions are being tested in trial NCT05711732?

The interventions under investigation include: MyCare Oncology Busulfan Assay Kit (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05711732?

This trial is sponsored by Saladax Biomedical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05711732 being conducted?

This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.